Provided by Tiger Fintech (Singapore) Pte. Ltd.

Evaxion Biotech A/S

1.86
+0.01000.54%
Post-market: 1.920.0599+3.22%18:11 EDT
Volume:16.23K
Turnover:30.48K
Market Cap:11.66M
PE:-0.10
High:1.92
Open:1.92
Low:1.85
Close:1.85
Loading ...

Company Profile

Company Name:
Evaxion Biotech A/S
Exchange:
NASDAQ
Establishment Date:
2008
Employees:
49
Office Location:
Dr. Neergaards Vej,5th Floor,Horsholm,Capital Region of Denmark,Denmark
Zip Code:
2970
Fax:
- -
Introduction:
Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Directors

Name
Position
Helen M. Boudreau
Independent Director
Jo Ann Suzich
Independent Director
Marianne Sogaard
Director, Chairperson of the board
Roberto Prego
Independent Director
Steven Projan
Independent Director

Shareholders

Name
Position
Lars Staal Wegner
Chief Executive Officer
Glenn S. Vraniak
Chief Financial Officer
Andreas Holm Mattsson
Chief Innovation Officer
Erik Deichmann Heegaard
Chief Medical Officer
Niels Iversen Moller
Chief Business Officer